Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma Sells 2,000 Shares

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the company’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $12.40, for a total transaction of $24,800.00. Following the completion of the sale, the president now directly owns 2,920,467 shares of the company’s stock, valued at approximately $36,213,790.80. This trade represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Songjiang Ma also recently made the following trade(s):

• On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.50, for a total transaction of $25,000.00.
• On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.70, for a total transaction of $25,400.00.
• On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.27, for a total transaction of $24,540.00.
• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.82, for a total transaction of $21,640.00.
• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.05, for a total transaction of $22,100.00.

Gyre Therapeutics Stock Performance

Shares of GYRE stock traded down $1.06 during mid-day trading on Monday, hitting $9.73. 313,303 shares of the stock traded hands, compared to its average volume of 196,608. The stock’s fifty day moving average is $12.49 and its two-hundred day moving average is $12.69. Gyre Therapeutics, Inc. has a 52-week low of $8.26 and a 52-week high of $27.10.

Institutional Trading of Gyre Therapeutics

Several hedge funds have recently modified their holdings of GYRE. Charles Schwab Investment Management Inc. lifted its position in shares of Gyre Therapeutics by 392.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after buying an additional 90,557 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Gyre Therapeutics by 16.9% during the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock valued at $3,808,000 after acquiring an additional 43,840 shares in the last quarter. Advantage Alpha Capital Partners LP acquired a new position in shares of Gyre Therapeutics during the third quarter valued at about $334,000. WINTON GROUP Ltd acquired a new position in shares of Gyre Therapeutics during the second quarter valued at about $220,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Gyre Therapeutics during the second quarter valued at about $218,000. 23.99% of the stock is owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.